Evidence map›Paper›PMID 41362022›Full record

ArticleBritish journal of haematology2026

A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.

Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alex ZadroRegenerative Medicine Division, Institute for Translational Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.ORCID https://orcid.org/0009-0003-1322-891X
Alberto ArribasInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Maria Vittoria ColomboRegenerative Medicine Division, Institute for Translational Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Eleonora CannasInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Filippo SprianoInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Luciano CascioneInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Afua Adjeiwaa MensahInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Federico SimonettaDivision of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Dalila PettaRegenerative Medicine Division, Institute for Translational Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Christian CandrianService of Orthopedics and Traumatology, Department of Surgery, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Chiara ArrigoniRegenerative Medicine Division, Institute for Translational Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.ORCID https://orcid.org/0000-0001-6808-1642
Francesco BertoniInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Matteo MorettiRegenerative Medicine Division, Institute for Translational Research, Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.

Funding

Fond'Action Contre le Cancer
6 · The paper itself

Abstract

Bone marrow (BM) involvement in B-cell non-Hodgkin lymphoma (B-NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high-throughput 3D BM co-culture model that faithfully reproduces key tumour-stroma interactions. In our system, BM stromal cells (BMSCs) decreased lymphoma cell sensitivity to Phosphatidylinositol 3-kinase (PI3K) and BTK inhibitors. Moreover, we show that our 3D platform enables the mechanistic studies of microenvironment-mediated drug resistance and has the potential to be developed into a tool for personalized therapeutic strategies for B-NHL.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmLymphoma, B-CellReceptors, Antigen, B-CellAgammaglobulinaemia Tyrosine KinaseBone MarrowCell Line, TumorCoculture TechniquesHumansPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsSignal TransductionTumor MicroenvironmentAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsReceptors, Antigen, B-CellBCR signalling targeted agentsin vitro 3D bone marrow modelnon‐Hodgkin B cell lymphomas

Identifiers

PMID41362022
PMCPMC12916189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.